|
Mammary Neoplasms
|
0.320 |
GeneticVariation
|
group |
LHGDN |
Gain of imprinting of SLC22A18 sense and antisense transcripts in human breast cancer.
|
16624517 |
2006 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
|
|
|
|
Rhabdomyosarcoma
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Because this region frequently is altered in neoplasms and in the genetic disease Beckwith-Wiedemann syndrome, we carried out a mutational analysis in tumor cell lines and Beckwith-Wiedemann syndrome samples that resulted in the identification of genetic alterations in the BWR1A gene: an insertion that introduced a stop codon in the breast cancer cell line BT549 and a point mutation in the rhabdomyosarcoma cell line TE125-T.
|
9520460 |
1998 |
|
Rhabdomyosarcoma
|
0.310 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Alcoholic Intoxication, Chronic
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Combining evidence from the case-control study, the follow-up in families, and gene expression provided strongest support for the association of a cluster of genes on chromosome 11 (SLC22A18, PHLDA2, NAP1L4, SNORA54, CARS, and OSBPL5) with alcohol dependence.
|
20201924 |
2010 |
|
Breast Cancer, Familial
|
0.300 |
GeneticVariation
|
disease |
ORPHANET |
|
|
|
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Rhabdomyosarcoma 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that SLC22A18 may act as a tumor suppressor by regulating the expression levels of cell growth-related proteins, and vinca alkaloids might show therapeutic efficacy against low-SLC22A18-expressing breast cancer.
|
30145211 |
2018 |
|
Bilirubin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases.
|
29403010 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrate CLImAT-HET's ability to accurately recover clonal compositions using tumor WGS data without a match normal sample.
|
28298214 |
2017 |
|
High density lipoprotein measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Exome-wide association study of plasma lipids in >300,000 individuals.
|
29083408 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of the 60 SDHD tumours investigated, four tumours showing retention of chromosome 11 showed SLC22A18 and CDKN1C expression levels comparable to levels in tumours showing loss of chromosome 11, suggesting loss of protein expression despite chromosomal retention.Our data strongly suggest that SLC22A18 and/or CDKN1C are tumour modifier genes involved in the tumourigenesis of SDHD-linked paraganglioma.
|
27402879 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, these findings offer the convincing evidence that the roles of SLC22A18 in NSCLC progression may be partially caused by the regulatory effects of miR-137, which may function as a tumor suppressor.
|
25498886 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In sum, we established SLC22A18 as a tumor suppressor in colon epithelial cells and propose that SLC22A18 is potentially a marker of diagnostic and prognostic values.
|
26196590 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The effect of SLC22A18 on the in vivo tumor radiosensitivity was investigated in the orthotopic mice model.
|
24481489 |
2014 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
SLC22A18 promoter methylation and protein expression were examined by methylation-specific polymerase chain reaction (MSP) and Western blotting respectively, then we compared SLC22A18 promoter methylation and protein expression in tumor cell explants in regard to prediction of TMZ response and survival time of 86 GBM patients.
|
23514245 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SLC22A18 [solute carrier family 22 (organic cation transporter) member 18] is located within the 11p15.5 cluster, and may be a new tumor suppressor gene; evidence of SLC22A18 hypermethylation is documented in several types of human cancers.
|
21993522 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SLC22A18 downregulation via promoter methylation is associated with the development and progression of glioma, suggesting that SLC22A18 is an important tumor suppressor in glioma.
|
21936894 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SLC22A18 expression was correlated with tumor size, lymph node metastasis, clinical stage, and extensive lyphovascular invasion.
|
21144813 |
2011 |
|
Bilirubin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association meta-analysis for total serum bilirubin levels.
|
19414484 |
2009 |
|
Bilirubin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association meta-analysis for total serum bilirubin levels.
|
19414484 |
2009 |
|
Bilirubin level result
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association meta-analysis for total serum bilirubin levels.
|
19414484 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TSSC5 (tumor-suppressing subchromosomal transferable fragment cDNA; also known as ORCTL2/IMPT1/BWR1A/SLC22A1L) is located in the region.
|
16314844 |
2006 |